Biopharma

Comprising esteemed institutions such as ICT Mumbai, IIT Bombay, TIFR, ACTREC, and Khalsa College, Mumbai, the biocluster aims to "revolutionise drug development" in the country.

Amid pandemic, India's biopharma and diagnostic industry proved to be strategic assets: Mansukh Mandaviya

In his video address to the National Summit on Quality of Biologicals, organised here by the National Institute of Biologicals (NIB), the minister said biological drugs have emerged as a choice of therapy along with conventional chemical drugs.

Most VCs in India don’t understand high science, hence don’t invest in bioscience start-ups: Kiran Mazumdar Shaw

VCs would rather invest in Swiggy or Zomato because that business is easy to understand, says the Executive Chairperson of Biocon and Biocon Biologics. The Biocon Biologics IPO is likely to happen in the year 2023/24, she adds.

Modi govt, World Bank line up $250 million to fund biotech startups

The Union Cabinet on Wednesday approved USD 250 million corpus as part of Biopharma Mission to fund biotech startups and accelerate innovation. World Bank has agreed to line up USD 125 million for the fund.

Suven Life gets patents for neurodegenerative drug

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's

Rationalising products to become specialised player: Biocon

Biocon's Kiran Mazumdar Shaw said the company deliberately took a hit on its topline in order to rationalize products. Biocon is focusing towards being a specialized products player.

Biocon says confident of maintaining margins in Q4

Third quarter sales for Biocon were lower than street's expectations (Rs 700 crore vs Rs 759 crore) but EBITDA was higher. This was due to margin expansion that resulted from temporary low R&D spend, said Kiran Mazumdar-Shaw. The company would maintain margins in the fourth quarter by changing product mix and focusing on high-margin products.

Drug pricing policy issue hurting sector's growth: Biocon

Biotechnology major Biocon which today posted a strong first quarter earnings raised concerns about confusion in the India drug pricing policy which has impacted the growth of the pharma-biotech sector.

UCB files cases against Ranbaxy, Glenmark, and others

Global biopharma company, UCB filed separate cases against 15 drug makers including Ranbaxy, Aurobindo, Zydus, Sun Pharma, Glenmark, Alembic Pharmaceuticals.

Biocon Q4: Analysts expect 9% drop in PAT to Rs 89.4cr

Pharmaceutical firm Biocon is set to declare its fourth quarter FY13 numbers on Thursday. Analysts on an average expect the company's profit after tax to fall by 9 percent year-on-year to Rs 89.4 crore due to lower operational performance, according to CNBC-TV18 poll.

Biocon Q3: Analysts expect PAT growing 6% to Rs 90 cr

Healthcare firm Biocon is set to declare its third quarter results on Thursday. Analysts on an average expect profit after tax of the company to grow by 6 percent year-on-year to Rs 89.6 crore in the quarter.

Biocon shrs drop after Q1 net rises lower-than-expected 13%

Biocon shares slipped 2% on Thursday after the biotechnology company reported lower-than-expected first quarter earnings. Its quarterly net profit rose 13% to Rs 79 crore, while net sales rose 30% to Rs 571 crore.

Biocon Q1 net down 9% to Rs 70 crore, shares fall

Biotechnology company Biocon's consolidated net profit for the first quarter fell almost 9% from a year ago to Rs 70.05 crore, while net sales were up over 10% to Rs 441.68 crore.

Pfizer partnership to give Biocon strong foothold in Europe

This quarter Biocon's net profit has risen 25% from the same period last year to 101 crore rupees, meeting analyst estimates and to keep this growth going, Biocon is shedding the fat, reports CNBC-TV18's Vineetha Athrey.